New Delhi: The vaccination drive against the coronavirus pandemic is underway across India and so far 197 crore doses of the vaccine have been administered. Thereafter, the vaccination drive against cervical cancer and typhoid may be launched soon. The Government Advisory Group (NTAGI) has recommended vaccination against cervical cancer and typhoid after examining the data.
According to sources, a separate HPV working group of the National Technical Advisory Group on Immunization against Cervical Cancer and Typhoid (NTAGI) had on June 8 examined the data of clinical trials and the utility of the vaccine for inclusion in the national immunisation function. According to official sources, the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO) had on June 15 recommended giving marketing permission for the vaccine. However, the drug controller general of India's (DCGI) permission is still awaited.
Sources said Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), has submitted an application to the Drugs Controller General of India (DCGI) of India and sought marketing permission for the vaccine to ensure its early availability in the country after the completion of phase 2/3 clinical trials with the support of the Department of Biotechnology. According to the application submitted by Prakash Kumar Singh, the vaccine, CERVAVAC, has shown a strong antibody response, which is about 1,000 times higher depending on all the targeted HPV types and all doses and age groups.